William G. Skelly

William G. Skelly (board member) discloses dealings in Acura Pharmaceuticals, Inc to SEC (Form 4). We count 50 filings; the first trade dates from 11 February 2006 and the latest from 2 January 2026.

In open-market terms, that means 1 purchase worth €8,449 on one side and 35 sales worth €258k on the other. Taken together, the sales exceed the purchases by €250k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 13 option exercises.

On 15 January 2026 came the latest disclosure, an option exercise in Acura Pharmaceuticals, Inc. The last purchase on record was published on 18 December 2017, which is 3,232 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.